Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models
- PMID: 24302770
- PMCID: PMC3864340
- DOI: 10.1073/pnas.1315875110
Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models
Conflict of interest statement
Conflict of interest statement: R.J.D. has a patent on thalidomide and analogs, including pomalidomide.
Comment in
-
Reply to D’Amato et al. and Zeldis et al.: Screening of thalidomide derivatives in chicken and zebrafish embryos.Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):E4820. doi: 10.1073/pnas.1318475110. Proc Natl Acad Sci U S A. 2013. PMID: 24471177 Free PMC article. No abstract available.
Comment on
-
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12703-8. doi: 10.1073/pnas.1307684110. Epub 2013 Jul 15. Proc Natl Acad Sci U S A. 2013. PMID: 23858438 Free PMC article.
References
-
- Lentzsch S, et al. S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 2002;62(8):2300–2305. - PubMed
-
- Smith RL, Fabro S, Schumacher H, Williams . Studies on the relationship between the chemical structure and embryotoxic activity of thalidomide and related compounds. In: Robson JM, Sullivan F, Smith RL, editors. Embryopathic Activity of Drugs, Biological Council Symposium. London: Churchill; 1965. pp. 194–209.
-
- Ito T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345–1350. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
